Alphyn Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $25M

  • Investors
  • 5

Alphyn General Information

Description

Developer of therapeutics for severe and prevalent skin diseases designed for multiple bioactive therapeutic drugs. The company's lead candidate for atopic dermatitis (AD) treats the bacterial cause and exacerbation of the disease, in addition to directly treating itch, inflammation, and infection that make AD so difficult to manage; it is also advancing a candidate for epidermolysis bullosa, enabling patients with a safe and effective cure for bacterial skin infections.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3724 Thomas Point Road
  • Annapolis, MD 21403
  • United States
+1 (410)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3724 Thomas Point Road
  • Annapolis, MD 21403
  • United States
+1 (410)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alphyn Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 12-Dec-2025 $25M Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 20-May-2022 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 30-Jun-2021 $2.48M $3.68M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 31-Mar-2020 $1.2M $1.2M Completed Startup
To view Alphyn’s complete valuation and funding history, request access »

Alphyn Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-4
Series A-3
Series A-2 5,500,000 $0.000100 8% $0.45 $0.45 1x $0.45 12.7%
Series A-1 3,200,000 $0.000100 8% $0.39 $0.39 1x $0.39 7.39%
To view Alphyn’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Alphyn Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutics for severe and prevalent skin diseases designed for multiple bioactive therapeutic drugs. The
Drug Discovery
Annapolis, MD
4 As of 2026

Wilmington, DE
 

Westlake Village, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alphyn Competitors (3)

One of Alphyn’s 3 competitors is Incyte, a Formerly VC-backed company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Incyte Formerly VC-backed Wilmington, DE
Arcutis Biotherapeutics Formerly VC-backed Westlake Village, CA
Dermavant Sciences Formerly PE-Backed Long Beach, CA
You’re viewing 3 of 3 competitors. Get the full list »

Alphyn Patents

Alphyn Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022226676-A1 Composition for treatment of topical dermatological bacterial skin conditions Pending 25-Feb-2021
CA-3209718-A1 Composition for treatment of topical dermatological bacterial skin conditions Pending 25-Feb-2021
EP-4297765-A1 Composition for treatment of topical dermatological bacterial skin conditions Pending 25-Feb-2021
EP-4297765-A4 Composition for treatment of topical dermatological bacterial skin conditions Pending 25-Feb-2021
US-12150970-B2 Composition for treatment of topical dermatological bacterial skin conditions Active 25-Feb-2021 A61K36/47
To view Alphyn’s complete patent history, request access »

Alphyn Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alphyn Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel Star Ventures Angel Group Minority
Opus8 PE/Buyout Minority
Angel Physicians Fund Angel Group Minority
Queen City Angels Angel Group Minority
Serial Stage Venture Partners Venture Capital Minority
To view Alphyn’s complete investors history, request access »

Alphyn FAQs

  • When was Alphyn founded?

    Alphyn was founded in 2019.

  • Where is Alphyn headquartered?

    Alphyn is headquartered in Annapolis, MD.

  • What is the size of Alphyn?

    Alphyn has 4 total employees.

  • What industry is Alphyn in?

    Alphyn’s primary industry is Drug Discovery.

  • Is Alphyn a private or public company?

    Alphyn is a Private company.

  • What is the current valuation of Alphyn?

    The current valuation of Alphyn is .

  • What is Alphyn’s current revenue?

    The current revenue for Alphyn is .

  • How much funding has Alphyn raised over time?

    Alphyn has raised $34M.

  • Who are Alphyn’s investors?

    Angel Star Ventures, Opus8, Angel Physicians Fund, Queen City Angels, and Serial Stage Venture Partners have invested in Alphyn.

  • Who are Alphyn’s competitors?

    Incyte, Arcutis Biotherapeutics, and Dermavant Sciences are competitors of Alphyn.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process